Quick Facts
| Property | Value |
|---|---|
| Category | Melanocortin Receptor Agonist |
| Risk Level | High |
| Administration | Subcutaneous Injection |
| Typical Frequency | PRN / 1–2 Times Weekly |
| Estimated Half-Life | Approximately 2–6 Hours |
| Primary Research Interest | Libido / Sexual Function / Arousal Signaling |
This material is provided strictly for educational and informational purposes related to peptide research and experimental sexual health compounds. PT-141 is a biologically active melanocortin receptor agonist capable of altering neurological and sexual arousal signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 0.5 mg = 0.100 mL (10.0 units)
• 1.5 mg = 0.300 mL (30.0 units)
• 2.0 mg = 0.400 mL (40.0 units)
2. Route of Administration
PT-141 is most commonly administered as a subcutaneous injectable melanocortin receptor agonist.
- Primary Route: SubQ Injection
- Preferred Timing: Several hours before anticipated sexual activity
- Administration Notes: Commonly used on an as-needed (PRN) basis rather than as a daily protocol
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: 0.5–1.5 mg, not to exceed 2 mg
- Frequency: 1–2 times per week as needed (PRN) for sexual activity. DO NOT EXCEED 8 TIMES PER MONTH.
- Cycle Length: Not cyclic (PRN)
- Special Notes: Many users commonly take a couple of weeks off after approximately 12 weeks of use in an attempt to reduce tolerance and receptor resistance concerns. PT-141 is also commonly discussed in conjunction with erectile dysfunction medications such as sildenafil and tadalafil.
4. Summary
PT-141 (Bremelanotide) is an experimental melanocortin receptor agonist peptide researched for its effects on libido, sexual arousal, and sexual function.
Unlike traditional erectile dysfunction medications that primarily influence blood flow, PT-141 is believed to act centrally through neurological arousal pathways.
5. Mechanism of Action
PT-141 activates melanocortin receptors involved in sexual arousal and neurological signaling.
- Enhanced libido signaling
- Increased sexual arousal
- Neurological stimulation of sexual response pathways
- Potential improvements in erectile function
- Possible enhancement of sexual desire in both men and women
The compound operates through central nervous system pathways rather than directly functioning as a vasodilator.
6. Potential Benefits
- Potential libido enhancement
- Improved sexual arousal signaling
- Possible erectile function support
- Potential enhancement of sexual desire
- May complement traditional ED medications
7. Potential Risks / Side Effects
High
- Nausea
- Flushing
- Headaches
- Elevated blood pressure
- Fatigue
- Dizziness
- Potential receptor desensitization with overuse
- Limited long-term human safety data
8. Half-Life
PT-141 is commonly discussed as having an estimated half-life of approximately 2–6 hours.
Effects on libido and arousal may persist substantially longer than the detectable plasma concentration.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Uncontrolled hypertension
- Severe cardiovascular disease
- Pregnancy or breastfeeding
- Use alongside stimulant compounds
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Melanocortin signaling literature
- Peer-reviewed sexual health journals
CKF Tide Tables 